ArticleJournal of hematology & oncology2022

FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.

Guangbing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.